Immuron (IMRN) Net Income towards Common Stockholders (2016 - 2024)
Immuron (IMRN) posted quarterly Net Income towards Common Stockholders of -$1.8 million for Q4 2024, up 15.22% year-on-year from -$1.5 million in Q1 2024, and up 15.22% on a QoQ basis from -$2.1 million in Q4 2023.
Immuron (IMRN) Net Income towards Common Stockholders (2016 - 2024) Analysis & Trends
Immuron (IMRN) has reported Net Income towards Common Stockholders for 9 consecutive years, with -$1.8 million the latest figure, recorded in Q4 2024.
- Quarterly Net Income towards Common Stockholders rose 15.22% year-over-year to -$1.8 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$1.8 million (up 15.22% YoY) and the FY2025 annual result came in at -$3.7 million, up 24.79% from the prior year.
- Net Income towards Common Stockholders improved to -$1.8 million in Q4 2024 per IMRN's latest filing, from -$2.1 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for IMRN reached as high as -$12792.9 in Q4 2021 and fell as low as -$2.1 million in Q4 2023.
- A 5-year average of -$931465.2 and a median of -$843881.6 in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders jumped 77.71% — and 2022, when it tumbled 2861.53%.
- Year by year, Net Income towards Common Stockholders stood at -$57387.7 in 2020, then soared by 77.71% to -$12792.9 in 2021, then slumped by 2861.53% to -$378866.2 in 2022, then slumped by 447.21% to -$2.1 million in 2023, then advanced by 15.22% to -$1.8 million in 2024.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$1.8 million, -$2.1 million, and -$1.3 million for Q4 2024, Q4 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,200.25 Bn | 66,199.96 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | -0.68 |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Immuron | 256.32 Mn | -28.05 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.76 Mn |
| Dec 31, 2023 | -2.07 Mn |
| Jun 30, 2023 | -1.31 Mn |
| Dec 31, 2022 | -378,866.23 |
| Dec 31, 2021 | -12,792.94 |
| Dec 31, 2020 | -57,387.72 |
| Dec 31, 2019 | -15,212.27 |
| Dec 31, 2018 | -1.58 Mn |
| Dec 31, 2017 | -1.89 Mn |
| Dec 31, 2016 | -3.45 Mn |
| Jun 30, 2016 | -4.39 Mn |